CD19 and diffuse large B-cell lymphoma: Three CD19 CART products, axi-cel, tisa-cel, and liso-cel, have been approved by FDA and EMA, to treat R/R DLBCL patients beyond 2 lines, and axi-cel has been recently approved by FDA as second line for adult patients with DLBCL refractory or relapsed within 12 months after first-line chemoimmunotherapy.